Cynvec


Cynvec is an innovative biotechnology company specializing in developing viral immunotherapies, particularly using Sindbis oncolytic viral vectors to treat cancer. Their proprietary experimental therapy targets tumors by harnessing the immune system, offering a novel approach to cancer treatment that can be administered via injection and effectively distributed throughout the body.

Industries

biotechnology
health-care
medical

Nr. of Employees

small (1-50)

Cynvec

New York, New York, United States, North America


Products

Sindbis vector candidate for systemic cancer immunotherapy (ovarian cancer focus)

An experimental Sindbis-based oncolytic viral vector platform paired with tumor-associated antigens to elicit systemic anti-tumor immune responses; intended for development against late-stage epithelial ovarian cancer (preclinical stage).


Services

In-house preclinical R&D activities to design, evaluate, and optimize Sindbis-based viral vectors and antigen pairings for oncology indications.

Execution of rodent (rat/mouse) tumor studies to assess tumor reduction, recurrence prevention, and immune memory following vector administration.

Expertise Areas

  • Viral immunotherapy development
  • Oncolytic vector engineering
  • Tumor microenvironment modulation
  • Tumor-associated antigen immunotherapy
  • Show More (4)

Key Technologies

  • Sindbis-based oncolytic vectors
  • Tumor-associated antigen targeting (NY-ESO-1)
  • LAMR (laminin receptor)-mediated tumor targeting
  • Intravenous and intraperitoneal systemic delivery
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.